On May 2, 2018, Novartis s Sandoz announced that it received a complete response letter (CRL) from FDA in response to the biologics license application (BLA) for the company s proposed rituximab biosimilar, which references Roche s Rituxan/MabThera (rituximab). Rituximab made CHF 7.3 billion (USOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.